Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)

Next Previous
X
Search
Trial Profile

Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms OMNIVORE

    • Most Recent Events

    • 24 Oct 2023 Results of pooled meta analysis from NCT03203473, NCT03117309, NCT02917772 assessing to better inform the activity of N+I after N presented at the 48th European Society for Medical Oncology Congress
    • 13 Apr 2022 Results identifying PD-L1 expression on circulating tumor cells as a prognostic indicator in this trial presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 05 Jan 2021 Planned primary completion date changed from 30 Nov 2020 to 30 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top